Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - nature.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'Hare, MS Zabriskie, AM Eiring… - Nature reviews …, 2012 - pubmed.ncbi.nlm.nih.gov
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
T O'Hare, MS Zabriskie, AM Eiring… - Nature reviews …, 2012 - europepmc.org
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
T O'Hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - search.ebscohost.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Erratum: Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'Hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - nature.com
On page 521 of this article, the passage discussing β-catenin as a regulator of gene
expression in chronic myeloid leukaemia should have cited the following article alongside …
expression in chronic myeloid leukaemia should have cited the following article alongside …
Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'Hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - go.gale.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
[引用][C] Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'Hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - cir.nii.ac.jp
Pushing the limits of targeted therapy in chronic myeloid leukaemia | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[引用][C] Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'HARE - Nat Rev Cancer, 2012 - cir.nii.ac.jp
Pushing the limits of targeted therapy in chronic myeloid leukaemia | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
T O'Hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - search.ebscohost.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …